Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Chemical structures of the ATP competitors imatinib, nilotinib,... | Download Scientific Diagram
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
Third-line therapy for chronic myeloid leukemia: current status and future directions | Journal of Hematology & Oncology | Full Text
An interesting commentary on the interpretation of the Nilotinib trial results – The Science of Parkinson's
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. - Abstract - Europe PMC
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors - ScienceDirect
Flying under the radar: the new wave of BCR–ABL inhibitors | Nature Reviews Drug Discovery
Pharmacology of Drugs: Nilotinib
Scheme explaining the synergistic effects of combining nilotinib and... | Download Scientific Diagram
Cells | Free Full-Text | Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy | HTML
Current status of therapy for chronic myeloid leukemia: a review of drug development | Future Oncology
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Why I Do Buy Biotech | Seeking Alpha
Frontiers | A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease | Cellular Neuroscience
Proposed mechanism of nilotinib in the regulation of pigmentation.... | Download Scientific Diagram
5MJC BCU 13: Tyrosine Kinases as Targets for Cancer Therapy | Research To Practice
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination - ScienceDirect
CML therapy : post-Gleevec® era - ppt download
Tolerance of Tyrosine Kinase Inhibitors among 33 Cancer Patients Followed in CHU Annaba-Algeria
